NEWS
Institutional Subscription: Comprehensive Analyses to Enhance Your Global and Local Impact
New Feature: Compare Your Institution with the Previous Year
Find a Professional: Explore Experts Across 197 Disciplines in 221 Countries!
Find a Professional
Print Your Certificate
New! Young University / Institution Rankings 2025
New! Art & Humanities Rankings 2025
New! Social Sciences and Humanities Rankings 2025
Highly Cited Researchers 2025
AD
Scientific Index 2025
Scientist Rankings
University Rankings
Subject Rankings
Country Rankings
Login
Register & Pricing
insights
H-Index Rankings
insights
i10 Productivity Rankings
format_list_numbered
Citation Rankings
subject
University Subject Rankings
school
Young Universities
format_list_numbered
Top 100 Scientists
format_quote
Top 100 Institutions
format_quote
Compare & Choose
local_fire_department
Country Reports
person
Find a Professional
Robert A. Copeland
Accent Therapeutics, Inc. - Boston / United States
Natural Sciences / Biological Science
AD Scientific Index ID: 4978701
Registration, Add Profile,
Premium Membership
Print Your Certificate
Ranking &
Analysis
Job
Experiences (0)
Education
Information (0)
Published Books (0)
Book Chapters (0)
Articles (0)
Presentations (0)
Lessons (0)
Projects (0)
Co-Authors
Subject Leaders
Editorship, Referee &
Scientific Board (0 )
Patents /
Designs (0)
Academic Grants
& Awards (0)
Artistic
Activities (0)
Certificate / Course
/ Trainings (0)
Association &
Society Memberships (0)
Contact, Office
& Social Media
person_outline
Robert A. Copeland's MOST POPULAR ARTICLES
1-)
Identification of a novel inhibitor of mitogen-activated protein kinase kinase MF Favata, KY Horiuchi, EJ Manos, AJ Daulerio, DA Stradley, WS Feeser, ... Journal of Biological Chemistry 273 (29), 18623-18632, 1998 35641998
2-)
Enzymes: a practical introduction to structure, mechanism, and data analysis RA Copeland John Wiley & Sons, 2000 2057*2000
3-)
Evaluation of enzyme inhibitors in drug discovery: a guide for medicinal chemists and pharmacologists RA Copeland John Wiley & Sons, 2013 14982013
4-)
Drug–target residence time and its implications for lead optimizationRA Copeland, DL Pompliano, TD MeekNature reviews Drug discovery 5 (9), 730-739, 200616212006
5-)
Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitorSR Daigle, EJ Olhava, CA Therkelsen, CR Majer, CJ Sneeringer, J Song, ...Cancer cell 20 (1), 53-65, 201110272011
ARTICLES
Add your articles
We use cookies to personalize our website and offer you a better experience. If you accept cookies, we can offer you special services.
Cookie Policy
Accept